<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73904">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957943</url>
  </required_header>
  <id_info>
    <org_study_id>LTX_SMOF_PRE_Eg</org_study_id>
    <nct_id>NCT01957943</nct_id>
  </id_info>
  <brief_title>Omega 3 Lipid Emulsions and Liver Transplantation</brief_title>
  <acronym>OTLT</acronym>
  <official_title>Impact of Pre-treatment of Living-donor Liver Transplant Recipients With Omega 3 Enriched Lipid Emulsions on Graft and Patient Outcome. A Prospective, Randomized, Multi-central Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <authority>Egypt: Mansoura faculty of medicine</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study Aims to investigate the possible benfecial impact of Omega 3 containing lipid
      emulsions on recepients for living donor liver transplantation. both perioperative and
      postoperative application of the study treatment are tested to determine the best time for
      drug adminstration.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Ischemia reperfusion injury</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver functions</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Renal functions</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Infection</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>lenght of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Reduction of Graft IR With Pretreatment of Omega 3</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>38 patients Will receive standard oral diet 3 days pefore the operation will receive placebo lipid supplementation 3 days before the operation with low omega 3 contents (Intralipid 10%)) Will receive same lipid supplementation for 5 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMEGA_PRE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>38 patients Will receive standard oral diet 3 days pefore the operation will receive lipid supplementation 3 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMEGA_POST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>38 patients Will receive standard oral diet 3 days pefore the operation will receive lipid supplementation 3 days before the operation with low omega 3 containing lipid emulsion (intralipid 10%) Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SMOFLipid</intervention_name>
    <arm_group_label>OMEGA_PRE</arm_group_label>
    <arm_group_label>OMEGA_POST</arm_group_label>
    <other_name>Omega 3 lipid emulsions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All liver transplant recepients

        Exclusion Criteria:

          -  Budd chiarri

          -  Previous upper abdominal surgery

          -  Retransplantation

          -  Known allergy to the study emulsion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr M Yassen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fawzia Abo elfetouh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amr M Yassen, Md</last_name>
    <phone>+201001497044</phone>
    <email>amryassen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Waleed R Elsarraf, MD</last_name>
    <phone>+201222322727</phone>
    <email>welsarraf@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver transplantation program - Gastroenterology surgical center - Mansoura university</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amr M Yassen, MD</last_name>
      <phone>+201001497044</phone>
      <email>amryassen@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>waleed R elsarraf, MD</last_name>
      <phone>+201222322727</phone>
      <email>welsarraf@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fawzia Abo elfetouh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 4, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Amr Mohamed Yassen</investigator_full_name>
    <investigator_title>Professor Doctor Amr M. Yassen</investigator_title>
  </responsible_party>
  <keyword>Omega 3</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Ischemia reperfusion</keyword>
  <keyword>graft function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
